Tumor Lysis Syndrome: Early Diagnosis and Management

Executive summary. Though eradication of cancer cells is the objective of anticancer therapy, the resulting release of potassium, nucleic acids, phosphates, and cytokines from dying cancer cells into the bloodstream can cause cardiac arrhythmias, renal failure, seizures, and even death. This multi-system complication, tumor lysis syndrome (TLS), has become more common with the introduction of new, highly effective cancer therapies. Every patient receiving chemotherapy should be monitored, but clinicians must know how to stratify patients by risk and match prophylaxis to risk category. Hydration plus a hypouricemic agent (allopurinol or rasburicase) forms the core of prevention, with rasburicase preferred in high-risk patients.

Introduction

The National Cancer Institute estimated that roughly 1.9 million people would be diagnosed with cancer in the United States in 2022. Given that prevalence, clinicians must be alert to the significant complications of cancer and its treatment, among the most serious of which is tumor lysis syndrome.

TLS is a common, acute, life-threatening condition seen primarily in patients with hematologic cancers and bulky, chemo-sensitive solid tumors. It can be triggered by the initiation of chemotherapy or occur spontaneously. The rapid lysis of proliferating tumor cells produces metabolic derangements (hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia), any of which can precipitate cardiac arrhythmia, seizures, renal failure, and sudden death. Because TLS can be lethal, early diagnosis is imperative, and that depends on vigilant risk assessment, prevention, laboratory monitoring, and aggressive intervention.

Epidemiology

Incidence and prevalence vary with the patient population, treatment regimen, and prophylaxis used. In a study of 788 adult and pediatric patients with acute leukemia or non-Hodgkin lymphoma, the incidence of laboratory versus clinical TLS was 18.9% versus 5%. The malignancies most often associated with TLS are non-Hodgkin lymphoma (30%), solid tumors (20%), acute myeloid leukemia (19%), and acute lymphocytic leukemia (13%).

When TLS does occur, the consequences can be fatal. Overall inpatient mortality is approximately 21%. Acute kidney injury (AKI) is the single most important predictor of poor outcomes: one French single-center study reported in-hospital and 6-month mortality of 51% and 66% in patients with TLS-related AKI, versus 7% and 21% in those without.

Pathogenesis

When massive tumor-cell lysis floods the bloodstream with potassium, phosphate, nucleic acids, and cytokines, several cascades follow. Nucleic-acid metabolism drives hyperuricemia, and uric acid precipitates in the renal tubules, causing renal dysfunction. Hyperphosphatemia binds calcium into complexes that deposit in tissue, producing hypocalcemia, which can lead to tetany, seizures, and arrhythmias. Hyperkalemia and decreased potassium clearance from AKI can cause muscle weakness, arrhythmia, and sudden death, while released cytokines can trigger a systemic inflammatory response.

Classification and diagnosis

Under the Cairo-Bishop system, TLS is classified as laboratory or clinical:

Laboratory TLS: two or more metabolic abnormalities (hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia) within 3 days before to 7 days after chemotherapy initiation.
Clinical TLS: laboratory TLS plus an increased creatinine level, seizures, cardiac dysrhythmia, or death.

A differential diagnosis should distinguish TLS from other causes of AKI, including sepsis, obstructive uropathy, nephrotoxic agents, contrast dye, rhabdomyolysis, vasculitis, and primary glomerulopathies. Work-up should include urinalysis and microscopy, a comprehensive metabolic panel, uric acid, LDH, complete blood count, and renal ultrasound.

Risk stratification and prevention

Every patient receiving chemotherapy should be assessed for TLS risk. Cairo-Bishop sorts patients into three categories: high (more than 5% develop TLS), intermediate (1% to 5%), and low (under 1%). Risk is escalated one level in the presence of renal dysfunction, renal involvement, or elevated uric acid, phosphate, or potassium.

Prophylaxis is matched to risk:

Low risk: monitoring and normal hydration, with no routine hyperuricemia prophylaxis.
Intermediate risk: monitoring, increased hydration, and allopurinol for up to 7 days (200 to 400 mg/m²/day in adults).
High risk: frequent monitoring, vigorous hydration, and rasburicase (0.1 to 0.2 mg/kg daily, up to 7 days). Rasburicase, a recombinant urate oxidase, converts urate into allantoin, a compound roughly 10 times more soluble than uric acid.

A thorough medication history matters, too: agents from intrathecal chemotherapy and steroids to thiazide diuretics and certain antibiotics can contribute to TLS and should be reviewed.

Management

Established TLS demands a multidisciplinary response from hospitalists, oncologists, hematologists, intensivists, and nephrologists.

Hydration is the first step: maintain urine output near 100 mL/m²/h with isotonic fluids (no added potassium), monitoring fluid balance with daily weights.
Hyperuricemia: switch to rasburicase, which lowers uric acid far more effectively than allopurinol once TLS is established.
Hyperphosphatemia and hypocalcemia: when hydration and rasburicase are insufficient, dialysis is indicated. Treat symptomatic hypocalcemia with calcium gluconate, but leave asymptomatic hypocalcemia alone to avoid further calcium-phosphate deposition.
Hyperkalemia: cardiac monitoring at K⁺ at or above 6 mmol/L; treat acute cardiotoxicity with calcium gluconate, plus IV salbutamol, insulin, and glucose.
Renal replacement therapy: reserved for refractory fluid overload or metabolic derangement; technique is chosen by laboratory data, cell turnover, and volume status.

Conclusion

TLS is an onco-metabolic emergency arising from rapid cell death, whether spontaneous or treatment-induced. As cancer therapies grow more effective, even malignancies once considered low risk can precipitate it. Clinicians should risk-stratify every hospitalized cancer patient and apply aggressive, risk-matched prophylaxis, with care delivered through close multidisciplinary collaboration.

Written by Heba Azzam as a medical writer at HMP Global. Published as a sponsored special report in the Journal of Clinical Pathways (January/February 2023). This is a readable adaptation; the designed publication is available as a PDF above. References available in the original.